Metabolic Therapy for Cancer Success Stories: 113+ Case Reports (2026 Edition)

By Editorial Team -

Table of Contents:

  • Introduction
  • Metabolic Therapy Case Series Compilation (alphabetical)
    1. Breast Cancer (83 cases)
    2. Brain Cancer 
    3. Lung Cancer 
    4. Prostate Cancer (29 cases)
  • Discussion and Conclusion

Important Disclaimer

It is important to acknowledge that the Metabolic protocol is not a universal cure for cancer. We do not advocate for or against any treatment—whether conventional (such as surgery, chemotherapy, radiation, immunotherapy), alternative, complementary, or adjunctive approaches. Our focus remains on effective and safe integrated and personalized strategies that may offer hope and improve outcomes for patients.

This article is not intended to be your definitive guide but rather a step in your journey toward the best possible health. It emphasizes that metabolic therapy and other approaches may form part of a comprehensive, multi-modal cancer treatment strategy tailored to your individual needs. For cancer patients and caregivers, these case reports give you structure, safety checkpoints, and conversation tools you can use with your doctor. We encourage you to seek additional resources, ask questions, and explore all available options, including conventional treatments such as surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, and hormone therapy, as well as emerging modalities. Personalized treatment plans developed with your healthcare team offer the best chance for effective management and improved outcomes.

Introduction: The Rise of Metabolic Therapy in Cancer Care

The field of oncology is generally based on three treatment areas: medical oncology, radiation oncology, and surgical oncology. However, another area is looming on the horizon, quickly gaining traction as a new and exciting frontier of cancer treatment.

Metabolic oncology, also known as cancer metabolism, studies how cancer cells reprogram the way they use energy and nutrients to support rapid growth and survival. Unlike normal cells, cancer cells rely on altered metabolic pathways—such as increased glucose uptake and inefficient energy production—to fuel their expansion.

Researchers in metabolic oncology aim to identify vulnerabilities within these altered pathways and develop therapies that selectively target cancer cells while sparing healthy tissue.

A useful way to visualize this is to imagine a tumor as a highly dependent city. It requires a constant influx of fuel, raw materials, and communication signals to survive and grow. Metabolic therapies seek to disrupt these supply lines—cutting off glucose, amino acids, lipids, and key signaling pathways—effectively starving the cancer while leaving normal cells relatively unharmed.

A 2026 large-scale population study published in Nature Communications demonstrated that machine learning-predicted insulin resistance was associated with increased risk of 12 cancer types in nearly 500,000 individuals from the UK Biobank. This finding strengthens a growing thesis:

Metabolic dysfunction is not merely a comorbidity — it may be a central modifiable axis in oncogenesis.

Metabolic oncology may also be particularly relevant in low- and middle-income countries, where access to expensive cancer therapies is often limited. Approaches that include repurposed drugs and metabolic interventions may offer comparatively lower-cost options, and in some cases the existing safety data from their original indications can help facilitate clinical evaluation and potential integration into practice. In this context, metabolic strategies and repurposing drugs are sometimes discussed as a way to help narrow disparities in access to cancer care between higher- and lower-resource settings.

Leading researchers have discovered innovative ways to prevent diseases from spreading and drastically improve patient outcomes. A groundbreaking approach is emerging in oncology that targets cancer cell metabolism. This innovative strategy targets the unique way cancer cells process energy and nutrients, offering new hope for patients and clinicians alike. 

Given the complexity of cancer treatment, it is crucial for patients to consult a specialized oncology team to determine the most appropriate course of action for their specific diagnosis.
 
Despite numerous anecdotal reports and media coverage suggesting that metabolic therapy may be effective in treating metastatic cancer, there is currently not enough clinical literature supporting its use as a stand-alone anti-cancer agent. 

This work-in-progress paper aims to compile anecdotal success stories and case reports to help establish a stronger scientific foundation for further investigation of metabolic therapy as part of a potential combination therapy for cancer.

Metabolic Therapy for Cancer Case Series Compilation

The following success stories were gathered from various web and social media sources, providing anecdotal, crowd-sourced information.

The list of metabolic therapy related cancer case reports below is organized alphabetically by cancer type.

Notes: 
  • Some cancer types have more than 10 case reports, so we’ve created dedicated articles for each to make updates and management easier. To view the complete set of case reports, click “Read More” under the relevant cancer type.
  • This is a lengthy article. To quickly find the specific cancer type you're looking for, use "Command + F" (Mac) or "Control + F" (Windows) to search the page.

1. Breast Cancer Success Stories (83 Cases)

In a study published in the Clinical Nutrition journal (2021), 80 patients with locally advanced and metastatic breast cancer were randomly assigned to a ketogenic diet or a control group for a 12-week treatment test. Patients in the ketogenic diet group had lower serum insulin levels, and their tumors shrank [Clinical Nutrition 2021].

A 47-year-old premenopausal woman with end-stage (T4N3M1) breast cancer treated with metabolically supported chemotherapy (MSCT), ketogenic diet (KD), hyperthermia (HT), and hyperbaric oxygen therapy (HBOT). Exploring other options, the patient was admitted to the ChemoThermia Oncology Center, Istanbul, Turkey in November 2018. At that time, the patient weighed 38 kg (body mass index: 18.1 kg/m2) and had extensive metastatic disease with lesions in the brain, lungs, mediastinum, liver, abdomen, and bones that were detected by magnetic resonance imaging of the brain (with contrast) and whole-body (18F)-fluorodeoxyglucose-positron emission tomography-computed tomography. The patient received a six-month treatment protocol comprised of MSCT, KD, HT, and HBOT, which eliminated all detectable lesions. The therapeutic response was sustained for two years with maintenance treatment comprising KD, dietary supplements, and repurposed medications. This single case report presents evidence of a complete and durable response to a treatment protocol combining MSCT and a novel metabolic therapy in a patient with end-stage breast cancer. (Cureus 2021)

Another case report highlights the influence of metabolically supported chemotherapy (MSCT), ketogenic diet (KD), hyperthermia (HT), and hyperbaric oxygen therapy (HBOT) in an overweight 29-year-old woman with stage IV (T4N3M1) triple-negative invasive ductal carcinoma of the breast. The patient presented with an observable mass in her left breast detected during a physical examination in December 2015. The patient received a treatment protocol consisting of MSCT, KD, HT, and HBOT. The patient continued to receive this treatment protocol and in April 2017 underwent a mastectomy, which revealed a complete pathological response consistent with the response indicated by her PET-CT imaging. This single case study presents evidence of a complete clinical, radiological, and pathological response following a six-month treatment period using a combination of MSCT and a novel metabolic therapy in a patient with stage IV TNBC. (Cureus 2017)

A 45-year-old woman in Ohio was diagnosed with breast cancer in late 2016. In August 2018, the cancer had spread and she developed tumors in her brain, lungs, mediastinum, liver, abdomen, and bones. Her doctor expected her to have less than a month to live. The patient began receiving stress pulse therapy in November 2018. In April 2019, the scan report indicated that the treatment was effective. According to the published study, her last check-up was in March 2021 and the results showed a stable condition, no recurrence, and improved quality of life [PubMed].

2. Brain Cancer Success Stories 

A 38-year-old man developed symptoms in February 2016 and was subsequently diagnosed with glioblastoma multiforme (the most common and malignant form of primary adult brain cancer). After 20 months of ketogenic diet therapy and completion of chemotherapy and radiotherapy, the patient’s tumor decreased by approximately 1.5 cm in diameter. He seemed in good health with no apparent clinical or neurological deficits [frontiersin.org].

3. Lung Cancer

Another 54-year-old man was diagnosed with lung cancer; the cancer cells had metastasized and tumors were found in his brain. Radiotherapy and chemotherapy had no effect, so the patient opted for a ketogenic diet. Two years later, the tumors in his brain and lungs shrank; after nine years of treatment, the brain and lung cancer tumors remained stable in size [Cureus 2022].

4. Prostate Cancer (29 cases)

The highest risk of death from prostate cancer is associated with increased waist circumference, increased blood pressure, hypertension, type 2 diabetes and obesity; thus, therapies that can reduce blood glucose levels have the potential to improve patient outcomes. A ketogenic diet, which requires fasting and has low carbohydrates, can lower blood sugar levels and control tumor growth. These findings support the hypothesis that elevated ketone bodies are associated with reduced tumor growth [Seyfried. Nature 2022]. 

Two papers published in Nature: Prostate Cancer and Prostatic Disease describe the therapeutic benefits of a low-carb diet and a fasting-mimicking diet for patients with prostate cancer [Chi. Nature 2022][Watt. Nature 2022]. 

This pilot prospective study (N=29) investigated the effect of a periodic fasting mimicking diet (FMD) on metabolic health factors in patients with Prostate Cancer [Watt. Nature 2022]. 

Systemic treatments for prostate cancer (PC) have significant side effects. Thus, newer alternatives with fewer side effects are urgently needed. Carbohydrate and Prostate Study 2 (CAPS2) trial was conducted in PC patients with biochemical recurrence (BCR) after local treatment to determine the effect of a 6-month LCD (low carbohydrate diet) intervention vs. usual care control on PC growth as measured by PSA doubling time (PSADT). The study results suggest a potential association of ketogenesis with slower PC growth and conversely glycolysis with faster PC growth. [Chi. Nature 2022]

Discussion and Conclusion

Diet plays an essential role in the daily life of patients with cancer, and dietary interventions have increasingly played a significant role in cancer clinical prevention and treatment strategies, achieving good treatment effectiveness (Zheng et al., 2022).

Numerous studies and clinical experiments have shown that KD has certain benefits in cancer treatment by influencing various processes, such as metabolism and immunity, to inhibit tumor growth. Therefore, it is more accurate to describe KD as a metabolic therapy rather than just a dietary approach (Oliveira et al., 2018). This treatment results in limiting energy acquisition by cancer cells, enhancing antitumor immune factors, and reducing immunosuppression. Furthermore, research has shown that KD with plant protein is more effective in assisting cancer treatment than KD with animal protein (Cai et al., 2022).

Combining KD with radiotherapy and chemotherapy can improve the sensitivity of tumor cells to conventional chemotherapy and radiotherapy, thereby enhancing the effectiveness of standard cancer treatment. Combining KD with immunotherapy can also significantly improve cancer treatment outcomes. Additionally, other nutritional interventions can have an impact on the effectiveness of KD in cancer treatment.

Moreover, KD can treat and improve complications that arise during chemotherapy, thereby enhancing cancer treatment effectiveness.

Although Ketogenic Diet offers the potential as a low-cost and relatively safe adjunctive measure for cancer treatment, it is far from being widely applicable based on current research. More extensive research and clinical trials are needed to explore and validate its effectiveness

Since these case reports lack a control arm, the biggest challenge remains identifying which patients will benefit from these treatments. That said, witnessing complete remissions in aggressive cancers with metabolic therapy and affordable repurposed drugs is a very encouraging sign.

The absence of RCTs (randomised controlled trials), as echoed by oncology consensus, underscores the imperative for rigorous trials, bioavailability optimizations, and real-world registries to distill signal from anecdote. Ethical imperatives demand equity: Ensuring low-resource patients aren't sidelined by regulatory silos or hype's uneven reach. 

It may take years for these anti-cancer agents to appear in mainstream medical journals, as bold results often provoke strong pushback. The most significant validation may come not from top journals but from a grassroots movement of patients and doctors with proven outcomes.

The momentum is undeniable but stand-alone metabolic therapy is not a silver bullet. It may have a place as pieces in your larger anti-cancer strategy. But cancer rarely succumbs to one or two interventions, however determined.

True empowerment comes from multi-layered action. Keep conversations open with professionals experienced in repurposing and metabolic approaches. You’re not alone—keep asking the hard questions, keep fighting smart, "as long as you try you cannot fail". 

Ultimately, these stories affirm that in medicine's grand narrative, patients are not passive recipients but co-authors. Armed with caution—consulting clinicians, tracking biomarkers, and prioritizing proven pillars. May this compilation propel not just hope, but hastened science. 
 
Cautionary Note: A strict long term ketogenic diet might cause liver failure due to the omega-6 fats in the diet. It's crucial to make sure the fats you eat are actually healthy. 

This 2026 review proposes a conceptual seven-layer metabolic intervention framework designed to target multiple metabolic vulnerabilities simultaneously. The framework integrates: 

  1. Metabolic modulation: Target glycolysis and mitochondria [1–5]

  2. Cancer-directed therapy

    • Surgery (when feasible)

    • Chemotherapy

    • Radiation therapy

    • Immunotherapy

  3. Immune optimization: Restore T-cell function [10–14]

  4. Microbiome support: Enhance treatment response [17–21]

  5. Adjunct therapies: Repurposed drugs, natural compounds [26–29]

  6. Dietary strategies: Improve metabolic environment [22–24]

  7. Lifestyle optimization: Reduce inflammation and insulin resistance [37–42]

The true scientific frontier may not lie in choosing between models, but in rigorously testing where each applies, where each falls short, and how they intersect.

Cancer biology is unlikely to be explained by a single axis—genetic or metabolic. A mature framework may ultimately require both.

For a more comprehensive understanding, it is worth exploring additional research studies and clinical trials. Always consult your healthcare provider before making any treatment decisions, as close monitoring and personalized care are essential.

References

🔬 Cancer Metabolism & Warburg Effect

  1. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033.

  2. Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41(3):211–218.

  3. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27–47.

  4. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21(3):297–308.

  5. DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200.

Metabolic Plasticity & Adaptation

  1. Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368(6487):eaaw5473.

  2. Martinez-Outschoorn UE, et al. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol. 2017;14(1):11–31.

  3. Vasan K, Werner M, Chandel NS. Mitochondrial metabolism as a target for cancer therapy. Cell Metab. 2020;32(3):341–352.

  4. Ashton TM, et al. Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res. 2018;24(11):2482–2490.

Immunometabolism & Tumor Microenvironment

  1. Buck MD, Sowell RT, Kaech SM, Pearce EL. Metabolic instruction of immunity. Cell. 2017;169(4):570–586.

  2. O’Neill LAJ, Kishton RJ, Rathmell J. A guide to immunometabolism. Nat Rev Immunol. 2016;16(9):553–565.

  3. Leone RD, Powell JD. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020;20(9):516–531.

  4. Biswas SK. Metabolic reprogramming of immune cells in cancer progression. Immunity. 2015;43(3):435–449.

  5. Colegio OR, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513(7519):559–563.

Tumor Microenvironment & Immune Suppression

  1. Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–4566.

  2. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–1437.

Microbiome & Cancer

  1. Routy B, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy. Science. 2018;359(6371):91–97.

  2. Gopalakrishnan V, et al. Gut microbiome modulates response to anti–PD-1 immunotherapy. Science. 2018;359(6371):97–103.

  3. Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF. The microbiome in cancer immunotherapy. Nat Rev Immunol. 2018;18(8):521–533.

  4. Matson V, et al. The commensal microbiome is associated with anti–PD-1 efficacy. Science. 2018;359(6371):104–108.

  5. Helmink BA, et al. The microbiome, cancer, and cancer therapy. Nat Med. 2019;25(3):377–388.

Diet, Fasting & Metabolic Therapy

  1. Longo VD, Mattson MP. Fasting: molecular mechanisms and clinical applications. Cell Metab. 2014;19(2):181–192.

  2. de Cabo R, Mattson MP. Effects of intermittent fasting on health and disease. N Engl J Med. 2019;381(26):2541–2551.

  3. Klement RJ. The emerging role of ketogenic diets in cancer treatment. Curr Opin Clin Nutr Metab Care. 2019;22(2):129–134.

  4. Seyfried TN, Flores RE, Poff AM, D’Agostino DP. Cancer as a metabolic disease. Carcinogenesis. 2014;35(3):515–527.

Repurposed Drugs & Adjunct Compounds

  1. Pantziarka P, et al. Repurposing drugs in oncology (ReDO). ecancermedicalscience. 2014;8:442.

  2. Pushpakom S, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41–58.

  3. Ashrafizadeh M, et al. Curcumin in cancer therapy. J Cell Physiol. 2020;235(12):9247–9266.

  4. Gupta SC, et al. Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep. 2011;28(12):1937–1955.

  5. OneDayMD, et al. Top 20 Alternative Cancer Treatments that Work: Evidence Based. OneDayMD. 2026.

Hallmarks of Cancer

  1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.

  2. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46.

Clinical Oncology & Immunotherapy

  1. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy. Science. 2015;348(6230):56–61.

  2. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355.

  3. Topalian SL, et al. Safety and activity of anti–PD-1 antibody. N Engl J Med. 2012;366(26):2443–2454.

Inflammation & Cancer

  1. Greten FR, Grivennikov SI. Inflammation and cancer. Nature. 2019;574(7775):27–37.

  2. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867.

Metabolism-Immune Crosstalk

  1. Chang CH, et al. Metabolic competition in the tumor microenvironment. Cell. 2015;162(6):1229–1241.

  2. Ho PC, et al. Phosphoenolpyruvate is a metabolic checkpoint of T cell function. Cell. 2015;162(6):1217–1228.

Insulin Resistance & Cancer

  1. Gallagher EJ, LeRoith D. Insulin resistance in cancer. Endocr Relat Cancer. 2015;22(5):R211–R224.

  2. Giovannucci E, et al. Diabetes and cancer. Diabetes Care. 2010;33(7):1674–1685.

Additional Supporting References

  1. DeBerardinis RJ. Tumor metabolism and its therapeutic implications. Annu Rev Med. 2012;63:19–32.

  2. Hensley CT, et al. Glutamine metabolism in cancer. Nat Rev Cancer. 2013;13(12):759–773.

  3. Pavlova NN. Emerging roles of metabolism in cancer therapy. Nat Rev Cancer. 2022.

  4. Sullivan LB, et al. Supporting roles of mitochondria in cancer. Cancer Cell. 2016.

  5. Lyssiotis CA, Kimmelman AC. Metabolic interactions in tumor microenvironment. Cell. 2017.

  6. Vander Heiden MG. Targeting cancer metabolism. Nat Rev Drug Discov. 2011.

  7. Schulze A, Harris AL. How cancer metabolism is tuned. Nature. 2012.

  8. Galluzzi L, et al. Metabolic control of immune response. Nat Rev Immunol. 2020.

Comments

Post a Comment

Labels

Show more

Archive

Show more

Popular posts from this blog

Fenbendazole, Ivermectin and Mebendazole Cancer Success Stories: 592 Case Reports Compilation (March 2026 Edition)

By Editorial Team -
Image
Table of Contents: Editor's Preface Introduction Fenbendazole Case Series Compilation (alphabetical) Breast Cancer Success Stories  (77 cases) Brain Cancer (including Glioblastoma) (119 cases) Bile Duct Cancer (Cholangiocarcinoma)  (4 cases) Bladder Cancer Success Stories  (including kidney cancer) (29 cases) Cervical Cancer  (6 cases) Colorectal Cancer  (including Appendix cancer) (51 cases) Esophageal and Stomach cancer (21 cases) Endometrial Cancer (9 cases) Gastric (Stomach) cancer (see  Esophageal and Stomach Cancer ) (21 cases) Head and Neck Cancer (15 cases) Kidney Cancer Case Series  (including urinary (urothelial) bladder cancer) (27 cases) Liver Cancer (HepatoCellular Cancer)  (3 cases) Lung Cancer (40 cases) Leukemia (9 cases) Lymphoma (23 cases) Melanoma (refer to Skin Cancer ) ...
Read more

Ivermectin and Fenbendazole: Treating Turbo Cancer - Dr William Makis

By Editorial Team -
Image
Ivermectin Resources I have seen tremendous demand for some sort of initial guidance “WHERE TO START” with High Dose Ivermectin for CANCER. Editor's Note: Dr Makis proposes four distinct cancer protocols for using Ivermectin in cancer treatment, specifically for patients who have developed turbo cancer or aggressive cancers. These protocols, referred to as the “Dr. Makis Ivermectin Cancer Protocols,” are categorized based on dosage and the severity of the cancer. Updated version I have an article and a video that go into depth: June 10, 2024 - "15 minutes with Dr.Makis" - Episode 018: High Dose Ivermectin and Cancer .  2025 - 2026 studies on ivermectin for cancer Clinical Yuan Yuan et al (Cedars-Sinai Medical Center) - A phase I/II study evaluating the safety and efficacy of ivermectin in combination with balstilimab in patients with metastatic triple negative breast cancer (ASCO 2025) Yuwen et al -  A Review of Ivermectin Use in Cancer Patients: Is it Time to Repurpose t...
Read more

Fenbendazole Joe Tippens Protocol: A Step-by-Step Guide (2026)

By Editorial Team -
Image
If you have been diagnosed with cancer, or have a loved one that is suffering from cancer, chances are you have heard about the Joe Tippens Cancer Protocol. The Fenbendazole Cancer Protocol has been gaining rapid interest over the past years following some fenbendazole advanced cancer success stories . We have seen tremendous demand for some sort of guide on how to use fenbendazole for cancer as there is also tremendous confusion both from the healthcare and non-healthcare communities. Joe Tippens founded the protocol (1) after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different mice body parts. The scientists discovered, through trial and error, a product in their canine product line, fenbendazole, that was batting 1.000 in killing these different cancers in the mice. The scientist was later diagnosed wit...
Read more

Ivermectin, Fenbendazole and Mebendazole Protocol in Cancer: Peer-Reviewed Protocol in Cancer

By Editorial Team -
Image
We are pleased to announce that the first-of-its-kind protocol utilizing Ivermectin, Mebendazole, and Fenbendazole for cancer treatment has been peer-reviewed and officially published on September 19, 2024. Spearheaded by leading researchers like Dr. Ilyes Baghli, Dr. Pierrick Martinez, and the FLCCC’s Dr. Paul Marik, this groundbreaking protocol harnesses the untapped power of Ivermectin, Mebendazole, and Fenbendazole, known for their effectiveness against parasites. Now, these drugs are showing potential to battle cancer, marking the dawn of a new treatment evolution. This trio of repurposed drugs has been shown to disrupt the growth of cancer cells, particularly by targeting microtubules, the essential structures that allow cancer to multiply uncontrollably. What makes this protocol even more potent is the synergistic effect when these drugs are used together, creating a powerful new affordable weapon against cancer. Journal of Orthomolecular Medicine 2024 Targeting the Mitochondri...
Read more

Ivermectin Tested against 28 types of Cancer: Most Sensitive vs Least Sensitive

By Editorial Team -
Image
A research group from Mexico investigated Ivermectin in Cancer. This is the first study that has tested as many as 28 Cancer types with Ivermectin.  Paper: 2020 (Juarez et al) - Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug.  Ivermectin was tested at 2mg/kg/day which translates to roughly 5uM in vitro concentration. The most sensitive cancer cell lines were: 1. Ovarian 2. Breast 3. Glioblastoma 4. Lung Cancer 5. Colon Cancer 6. Uterine SCC 7. hepatocellular 8. breast TNBC 9. Pancreatic 10. Endometrial. Least sensitive were: 1. osteosarcoma 2. gastric 3. melanoma  Although lymphoma and leukemia cell lines appear to be more resistant to Ivermectin, Ivermectin has a significant impact on those cells' ability to form colonies. So yes, Ivermectin is useful against BOTH lymphomas and leukemias.  Ivermectin also goes after CANCER STEM CELLS, which tend to be resistant to chemotherapy: ...
Read more

Best Ivermectin Dosage for Humans with Cancer or Different Cancer Types (2026)

By Editorial Team -
Image
Introduction This article discusses dosage considerations and key factors regarding the use of ivermectin in cancer treatment. Commonly available information about ivermectin dosages is often inaccurate when applied to potential cancer-related uses.  Many sources cite standard dosages recommended by Merck for treating parasitic infections, rather than dosages studied specifically in the context of cancer research. The anti-parasitic dosage is not as effective for people looking for a dosage against cancer. Dosage will need to be adjusted according to the  current weight, the type of Cancer, the stage and grade of the Cancer and the health of the liver. Ivermectin dosage should also be based on ivermectin cancer studies. Multiple factors are considered including studies including ivermectin for cancer, anecdotal studies and case series, the aggressiveness of the cancer type and the cancer stage. It also takes into account the types of medications the person uses. For example, i...
Read more

Dr William Makis Ivermectin Protocol 2026 – Complete Guide + Patient Outcomes

By Editorial Team -
Image
Dr. William Makis MD (McGill Medicine, 110+ peer-reviewed publications) runs the world's largest high-dose ivermectin cancer clientele in 2025 – he has guided thousands of patients globally with remarkable results in turbo cancers and conventional failures. This continuously updated 2026 guide compiles Dr. Makis's latest protocols (from his Substack, X posts through 2026, and direct patient correspondence). We cross-reference his exact dosages, schedules, combinations, safety data, sourcing, and real patient outcomes (anonymized but verifiable on his channels). Important Disclaimer: This content is for educational purposes only and does not constitute medical advice. Ivermectin is used off-label for cancer treatment. Always consult with a knowledgeable physician whom you trust to manage your health. Individual results may vary. Do not self-medicate with ivermectin without proper bloodwork and medical monitoring, as misuse can lead to serious side effects and drug interactions. ...
Read more

Ivermectin Dosage Guide for Humans (2025)

By Editorial Team -
Image
In this Article: Overview of Ivermectin Dosage | Ivermectin Dosage for Adults | Ivermectin Dosage for Children | Ivermectin dosage restrictions | How to take ivermectin | Ivermectin dosage FAQs The prescribed dosage for ivermectin oral tablets depends on the type of parasitic infection you have and your body weight. Ivermectin is typically taken as a single dose. Repeat doses may be needed in some cases. Specifically, ivermectin oral tablet is approved by the Food and Drug Administration (FDA) to treat the following conditions in adults and certain children: a parasitic infection in the intestinal tract called strongyloidiasis a parasitic infection of the eyes and skin called onchocerciasis  (River Blindness) Ivermectin oral tablet is a generic medication and belongs to a drug class called antiparasitic medications. It is also available in a brand-name version called Stromectol. This article describes the dosages of ivermectin oral tablets, as well as the medication’s streng...
Read more

DMSO 101: Benefits, Uses, Dosage and Side Effects (2026)

By Editorial Team -
Image
In 2022, Erica Eyres, a vigorous fifty-six-year-old aerobics instructor who had struggled to breathe, was given “absolutely devastating” news: She might need a lung transplant. She had never smoked, ran cross-country track in high school, and was a personal trainer for years, but, by 2024, a transplant assessment was arranged. (1) “I decided that I will make that decision,” she said, “only if it’s the last resort, and I’m on my deathbed.” A few months before her consultation, however, Eyres, then fifty-eight, made an appointment with a new primary care doctor for routine prescription refills. She was about to be introduced, literally and figuratively, to a new kind of medicine. It would change everything. DMSO Online Buying Guide (Paid Link) Buy on Amazon Disclosure: OneDayMD.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program that enables sites to earn advertising fees by advertising and linking to Amazon.com, but this is at NO extra co...
Read more

Best Fenbendazole Dosage for Humans: Safety, Side Effects and Efficacy Examined (2026)

By Editorial Team -
Image
Fenbendazole is a broad spectrum anti-parasitic used against gastrointestinal parasites including: giardia, roundworms, hookworms, whipworms, the tapeworm genus Taenia (but not effective against Dipylidium caninum, a common dog tapeworm), pinworms, aelurostrongylus, paragonimiasis, strongyles, and strongyloides that can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits, most reptiles, freshwater shrimp tanks as planaria and hydra treatments, as well as seals. (2) Fenbendazole, has garnered ⁤attention​ for its potential use ​in‍ humans.‍ The Fenbendazole Cancer Protocol gained rapid interest over the past years following some fenbendazole advanced cancer success stories  (more than 500 case reports). Joe Tippens founded the protocol  after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different m...
Read more